Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
Diabetes, Obesity and Metabolism · 2025-06 · 27 (6) · 3357-3366
DOI: 10.1111/dom.16353 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.03.2025. Verfasst von Jheng-Yan Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Bariatric Surgery, Obesity. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Aims
This real‐world study compared clinical outcomes between tirzepatide treatment and bariatric metabolic surgery (BMS) in adults with obesity.
Methods
This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m 2 . Patients initiating tirzepatide treatment were compared with those undergoing BMS. The primary outcome was all‐cause mortality, while secondary outcomes included major adverse cardiovascular events (MACEs) and major adverse kidney events (MAKEs). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated, and stratified analyses were performed based on age, sex and BMI categories.
Results
After exclusions and 1:1 propensity score matching (PSM), 84 884 matched pairs were analysed. The incidence of all‐cause mortality was 0.19 per 100 person‐years in the tirzepatide group compared with 0.57 in the BMS group. Tirzepatide was associated with a significantly lower risk of all‐cause mortality compared with BMS (HR, 0.311; 95% CI, 0.257–0.375; p < 0.0001). The mortality benefits were consistent across age groups, genders and BMI categories. Tirzepatide also reduced the risk of MACEs (HR, 0.743; 95% CI, 0.673–0.821; p < 0.0001) and MAKEs (HR, 0.375; 95% CI, 0.336–0.419; p < 0.0001). Stratified analyses demonstrated significant reductions in primary and secondary outcomes across most categories.
Conclusion
Tirzepatide demonstrated superior clinical outcomes compared with BMS in adults with obesity, including significant reductions in all‐cause mortality, MACEs and MAKEs. These findings suggest that tirzepatide may serve as an effective non‐surgical alternative to BMS, with broad applicability across diverse patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Division of Preventive Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
ORCID-Profile: Chih-Cheng Lai
Zitieren
APA
Wu, J. Y., Chan, S. E., Hsu, W. H., Kuo, C. C., Tsai, Y. W., Liu, T. H., Huang, P. Y., Chuang, M. H., Yu, T., & Lai, C. C. (2025). Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study. Diabetes, Obesity and Metabolism, 27(6), 3357-3366. https://doi.org/10.1111/dom.16353
Vancouver
Wu JY, Chan SE, Hsu WH, Kuo CC, Tsai YW, Liu TH, et al. Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study. Diabetes, Obesity and Metabolism. 2025;27(6):3357-3366. doi:10.1111/dom.16353
BibTeX
@article{Wu2025,
author = {Wu, Jheng-Yan and Chan, Song-En and Hsu, Wan-Hsuan and Kuo, Chia-Chih and Tsai, Ya-Wen and Liu, Ting-Hui and Huang, Po-Yu and Chuang, Min-Hsiang and Yu, Tsung and Lai, Chih-Cheng},
title = {Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {6},
pages = {3357--3366},
doi = {10.1111/dom.16353}
}
EUVIMED